Rationale and design of a phase II trial of pyrotinib in combination with nab-paclitaxel as adjuvant therapy for N0/N1mi, HER2 + early breast cancer (PHAEDRA).

MLA

Wang, Changjun, et al. “Rationale and Design of a Phase II Trial of Pyrotinib in Combination with Nab-Paclitaxel as Adjuvant Therapy for N0/N1mi, HER2 + Early Breast Cancer (PHAEDRA).” BMC Cancer, vol. 22, no. 1, Mar. 2022, pp. 1–7. EBSCOhost, https://doi.org/10.1186/s12885-022-09346-1.

APA

Wang, C., Zhou, Y., Lin, Y., Mao, F., Guan, J., Zhang, X., Shen, S., Wang, X., Zhang, Y., Pan, B., Zhong, Y., Peng, L., Cao, X., Yao, R., Zhou, X., Xu, C., Xu, Y., & Sun, Q. (2022). Rationale and design of a phase II trial of pyrotinib in combination with nab-paclitaxel as adjuvant therapy for N0/N1mi, HER2 + early breast cancer (PHAEDRA). BMC Cancer, 22(1), 1–7. https://doi.org/10.1186/s12885-022-09346-1

Chicago

Wang, Changjun, Yidong Zhou, Yan Lin, Feng Mao, Jinghong Guan, Xiaohui Zhang, Songjie Shen, et al. 2022. “Rationale and Design of a Phase II Trial of Pyrotinib in Combination with Nab-Paclitaxel as Adjuvant Therapy for N0/N1mi, HER2 + Early Breast Cancer (PHAEDRA).” BMC Cancer 22 (1): 1–7. doi:10.1186/s12885-022-09346-1.